ProQR (PRQR) AI Stock Analysis

• Market Cap: $241.99M
• Dividend Yield: N/A
• Average Volume (3M): 337.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.73
• Revenue Growth: 82.38%
• EPS Growth: 3.63%
• Country: US
• Employees: 166
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -0.12
• Shares Outstanding: 105,212,524
• 10 Day Avg. Volume: 356,443
• 30 Day Avg. Volume: 337,008
• PEG Ratio: 0.73
• Price to Book (P/B): 3.78
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.58
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $8.63
• Price Target Upside: 271.98% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 51 Neutral
• Price Target: $2.00 ▼(-13.79%Downside)

ProQR's stock score is primarily influenced by its financial performance, which shows strong revenue growth but significant profitability and cash flow challenges. Technical analysis indicates short-term bullish momentum, contributing positively to the score. However, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation, limiting the overall attractiveness of the stock.

Positive Factors

Investment and Funding

Rett opportunity is underappreciated and PRQR received funding from the Rett Syndrome Research Trust, which could open the door to other common RTT mutations.

Partnerships

Partnership with Eli Lilly underscores platform value and opens the door for milestone payments down the road.

Technological Advancements

The next generation AX-0810 with nearly 5.5-fold increase in potency over early generation NTCP EONS and with improved stability profile in vitro with no hepatotoxicity or immunostimulatory potential hints at potential good PK/PD and safety profile.

Negative Factors

Clinical Trials

The first clinical data of AX-0810 in healthy volunteers will provide key information regarding target engagement and biomarkers.

Market Competition

PRQR is one of just 3 public biotechs with ADAR capabilities, offering exposure to rare indications as well as highly prevalent cardiovascular and liver diseases.

ProQR Business Overview & Revenue Model

Company Description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

How the Company Makes Money

ProQR Therapeutics generates revenue primarily through strategic collaborations and partnerships with other pharmaceutical and biotechnology companies. These collaborations often involve licensing agreements, research funding, milestone payments, and royalties on product sales. Additionally, the company may receive grant funding from various institutions to support its research and development efforts. ProQR's financial performance largely depends on the successful advancement of its clinical pipeline and securing partnerships to commercialize its RNA therapy candidates.

ProQR Financial Statement Overview

Summary

ProQR exhibits strong revenue growth, indicative of expanding operations. However, persistent net losses and negative cash flows highlight financial instability. The balance sheet reflects a relatively healthy leverage position, but the company's path to profitability and positive cash flow remains uncertain.

Income Statement

ProQR has shown significant revenue growth, increasing from $1.35M in 2021 to $19M in TTM 2025. The gross profit margin is strong, but the company is still operating at a net loss, with net profit margins remaining negative. The EBITDA margin is also negative, indicating challenges in achieving operational profitability.

Balance Sheet

The debt-to-equity ratio is relatively low, suggesting manageable leverage levels. The equity ratio shows a stable capital structure with a moderate proportion of equity funding. However, the company has been operating with negative net income, impacting return on equity negatively.

Cash Flow

ProQR has faced issues with free cash flow, which has remained negative, impacting its liquidity position. The operating cash flow to net income ratio is unfavorable due to consistent net losses. Despite this, financing activities have provided cash inflows, supporting operational needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	19.01M	18.91M	6.51M	4.04M	1.35M	0.00
Gross Profit	18.29M	18.91M	6.38M	1.56M	1.35M	-2.19M
EBITDA	-27.17M	-24.12M	-24.10M	-56.46M	-54.95M	-136.56M
Net Income	-30.18M	-27.76M	-28.12M	-64.89M	-61.68M	-46.61M
Balance Sheet
Total Assets	151.69M	167.96M	137.88M	171.32M	209.58M	98.73M
Cash, Cash Equivalents and Short-Term Investments	132.41M	149.41M	118.92M	94.78M	187.52M	75.84M
Total Debt	16.85M	17.22M	19.73M	21.97M	60.37M	34.28M
Total Liabilities	72.75M	79.40M	96.49M	106.21M	96.35M	42.18M
Stockholders Equity	78.94M	88.56M	41.39M	65.50M	113.83M	57.09M
Cash Flow
Free Cash Flow	-37.97M	-37.81M	20.18M	-69.22M	-26.50M	-47.98M
Operating Cash Flow	-37.06M	-36.39M	21.55M	-68.51M	-26.01M	-47.06M
Investing Cash Flow	13.44M	-4.07M	4.28M	-702.00K	-425.00K	-924.00K
Financing Cash Flow	70.19M	70.28M	-2.27M	-30.89M	136.83M	14.50M

ProQR Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Positive. The current price of 2.32 is above the 20-day moving average (MA) of 2.08, above the 50-day MA of 1.85, and above the 200-day MA of 2.30, indicating a bullish trend. The MACD of 0.13 indicates Negative momentum. The RSI at 68.94 is Neutral, neither overbought nor oversold. The STOCH value of 66.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PRQR.

ProQR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TNXP	61 Neutral	$282.22M	―	-91.44%	―	-2.04%	83.49%
SEER	55 Neutral	$127.70M	―	-24.73%	―	-1.02%	-8.59%
CGEN	54 Neutral	$156.17M	87.50	-24.22%	―	-23.40%	17.80%
RGLS	52 Neutral	$564.95M	―	-53.82%	―	―	44.85%
SLN	52 Neutral	$306.05M	―	-99.23%	―	-40.10%	-16.60%
PRQR	51 Neutral	$241.99M	―	-52.64%	―	82.38%	3.63%
Sector *	46 Neutral	C$203.97M	-3.15	-23.14%	2.72%	21.17%	-0.61%